Doximity

Doximity is a San Francisco professional network for American medical professionals (NYSE: DOCS), founded in 2010, and the company says its members include more than 85 percent of US physicians. It is best known for the network itself, a telehealth dialer that hides a doctor's personal number, and news and hiring tools. It is not an AI-native company, but it now builds and ships its own clinical AI: Doximity Ask, an evidence-grounded clinical assistant renamed from Doximity GPT in May 2026, and Doximity Scribe, an ambient note-taking tool, both free to verified US clinicians. Those tools are not what it sells. Its paying customers are mainly pharmaceutical manufacturers and health systems, which buy marketing and hiring services aimed at its members.

Its AI pattern is distribution-first: the asset is the verified network, and AI is a set of free tools meant to bring clinicians back to it every day. Ask began in 2023, months after ChatGPT, as a HIPAA-compliant assistant for clinical questions and paperwork such as prior authorization letters. In July 2025 Doximity released Scribe to verified physicians, nurse practitioners, physician assistants and medical students after more than a year of beta testing, saying it discards the audio once a note is written. The same month it closed the purchase of Pathway Medical, a Montreal startup building an AI clinical reference, for 26 million dollars in cash plus up to 37 million dollars in equity grants, and folded Pathway's medical corpus and model into Ask.

In December 2025 it announced PeerCheck, which puts physician review into Ask's answers, with Eric Topol and former US Surgeon General Regina Benjamin as co-editors-in-chief. By August 2026 the company cited more than 11,000 physician reviewers. In May 2026 it said more than 800,000 prescribers had used its workflow tools in a quarter and nearly half of them had used its clinical AI. In August 2026 it said Ask was the top-performing US-based model in NOHARM, a clinical safety benchmark from Stanford and Harvard researchers. That result covers one slice of the study, and AMBOSS, a German rival, says its own tool ranked first overall.

The AI push also brought a lawsuit. In June 2025 OpenEvidence sued Doximity in federal court in Massachusetts, alleging that Doximity employees used physicians' provider numbers to get into its clinician-only tool and tried to extract its confidential instructions through prompt injection. Doximity disputes the claims, and in September 2025 it filed counterclaims alleging a misinformation campaign, harassment of its employees and public disclosure of patient information. In January 2026 the judge let most claims on both sides proceed, and in September 2026 the case was still in discovery. None of the allegations has been proven.

The honest framing: Doximity's value rests on a network that most American doctors already use and on the drug makers and hospitals that pay to reach them. AI is a lever on top, designed to make that network a daily habit rather than an occasional stop. The usage figures are the company's own, and the benchmark lead is real but narrow; the same study found that most harmful errors across every tool tested were omissions rather than wrong facts. Unlike OpenEvidence, which was built as an AI product from the start, or Abridge, which sells its scribe to health systems, Doximity gives its AI away to protect a business built on something else.